Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MetaVia Inc. (MTVA : NSDQ)

• Company Description    MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.72 Daily Weekly Monthly 20 Day Moving Average: 103,456 shares Shares Outstanding: 19.59 (millions) Market Capitalization: $14.06 (millions) Beta: 0.21 52 Week High: $5.16 52 Week Low: $0.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.27% -7.85% 12 Week -2.84% -18.28% Year To Date -64.63% -66.88%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 545 Concord Avenue Suite 210 - Cambridge,MA 02138 USA ph: 857-702-9600 fax: 734-293-0444 ir@metaviatx.com http://www.metaviatx.com

• General Corporate Information    Officers Hyung Heon Kim - Chief Executive Officer; President and Director Andrew I. Koven - Chairman of the Board Marshall H. Woodworth - Chief Financial Officer Mark A. Glickman - Director Jason L. Groves - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 64132R404 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 19.59 Most Recent Split Date: 12.00 (0.13:1) Beta: 0.21 Market Capitalization: $14.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 72.73% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -222.13 12/31/24 - -221.17 ROA 06/30/25 - - 03/31/25 - -123.85 12/31/24 - -131.12 Current Ratio 06/30/25 - - 03/31/25 - 1.55 12/31/24 - 1.94 Quick Ratio 06/30/25 - - 03/31/25 - 1.55 12/31/24 - 1.94 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.51 12/31/24 - 0.92 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©